We are investigating the mechanisms by which cancer mutations deregulate the normal processes of cellular function and growth ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) in combination with ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Zhejiang Provincial Key Lab for Chemical and Biological Processing Technology of Farm Product, School of Biological and Chemical Engineering, Zhejiang University of Science and Technology, Hangzhou ...

Inhibitors that target key components of this pathway, including PI3K, AKT and mammalian target of rapamycin (mTOR), are being actively developed. Some of them have reached clinical trials in ...

Murine Kras-driven lung cancer models have confirmed the key requirements for RAF, PI3K and RAL-GEF in vivo. Co-opted pathways required by oncogenic KRAS in order to sustain lung tumorigenesis ...

EGF receptor (EGFR) inhibitor could block KLK8-induced activation of PI3K/Akt/mTOR pathway and attenuate pro-proliferation and anti-apoptotic of KLK8 in Mia-paca-2 and Panc-1 cells. In conclusion, ...

EGFR functions by activating many intracellular signaling pathways following binding of various ligands ... EGFR phosphorylation at Y1068 leads to PI3K-Akt signaling, a phenomenon that may be ...